Respiratory News and Research

RSS

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

Research roundup: Compounding pharmacies; marketplace details; changes in insurance coverage

Outraged over a 2012 fungal meningitis outbreak traced back to Framingham, Massachusetts-based drug compounder New England Compounding Center (NECC) that left sixty-four people dead and more than 700 sickened, Congress passed the Compounding Quality Act .

5 May 2014

Tens of thousands of premature deaths could be prevented each year

Heart disease, cancer, chronic lower respiratory diseases, stroke, and unintentional injuries cause nearly 900,000 premature deaths in the US each year. A recent study showed that 20–40% of deaths from each of these causes could be prevented.

2 May 2014

FDA approves Parion’s investigational new drug application for treatment of dry eye disease

Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.

2 May 2014

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237).

30 Apr 2014

Boehringer announces first results of Phase III INPULSIS trials at 2014 ATS International Conference

Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 - 21 May in San Diego

30 Apr 2014

Study: Electronic cigarette "vapors" may worsen acute respiratory diseases among youth

Electronic cigarette "vapors" are made of small particles containing chemicals that may cause or worsen acute respiratory diseases, including asthma and bronchitis, among youth, according to a new study by RTI International.

30 Apr 2014

Study documents occupational exposure to waste anesthetic gases in PACU

Teleflex Incorporated (NYSE: TFX): A study published in the Journal of PeriAnesthesia Nursing (JOPAN) documents occupational exposure to waste anesthetic gases (WAG) in the post-anesthesia care unit (PACU) may be higher than standards recommend.

29 Apr 2014

Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.

29 Apr 2014

Study: Genetics as well as environment in womb play important roles in development of baby

A recent study led by A*STAR's Singapore Institute for Clinical Sciences (SICS) found that genetics as well as the environment in the womb play important roles in the development of the baby.

29 Apr 2014

Researchers develop animal model of human hantavirus pulmonary syndrome

National Institutes of Health (NIH) researchers have developed an animal model of human hantavirus pulmonary syndrome (HPS) in rhesus macaques, an advance that may lead to treatments, vaccines and improved methods of diagnosing the disease.

29 Apr 2014

Scientists identify natural human antibodies against virus that causes MERS

Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.

29 Apr 2014

Scientists extract infectious sample of MERS coronavirus from two camels in Saudi Arabia

There is new, more definitive evidence implicating camels in the ongoing outbreak of Middle East Respiratory Syndrome, or MERS. Scientists at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health, King Saud University, and EcoHealth Alliance extracted a complete, live, infectious sample of MERS coronavirus from two camels in Saudi Arabia.

29 Apr 2014

Positive results from pivotal clinical trial of Trophos’ olesoxime in SMA patients to be presented at AAN 2014

Trophos and AFM-Telethon today announce that data from the pivotal clinical trial of Trophos’ lead product candidate olesoxime in spinal muscular atrophy (SMA) will be presented during the 66th American Academy of Neurology annual meeting to be held in Philadelphia, PA, USA, from April 26 to May 3 2014.

29 Apr 2014

Immunoregulatory genes modulate otitis media risk

Variation in genes involved in immunity influences children’s susceptibility to developing otitis media, according to research by a US team.

28 Apr 2014

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GlaxoSmithKline plc and Theravance, Inc. today announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US.

28 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

Mauna Kea receives regulatory approval in Japan for Cellvizio flagship product

Mauna Kea Technologies, leader in the optical biopsy market, announced today it received regulatory approval in Japan for the company's Cellvizio flagship product.

28 Apr 2014

Study: Depression affects more than one out of three critical care survivors

Depression affects more than one out of three survivors of critical illness, according to a Vanderbilt study released in The Lancet Respiratory Medicine, and the majority of patients experience their symptoms physically rather than mentally.

26 Apr 2014

Respiratory News and Research

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Research roundup: Compounding pharmacies; marketplace details; changes in insurance coverage

Tens of thousands of premature deaths could be prevented each year

FDA approves Parion’s investigational new drug application for treatment of dry eye disease

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Boehringer announces first results of Phase III INPULSIS trials at 2014 ATS International Conference

Study: Electronic cigarette "vapors" may worsen acute respiratory diseases among youth

Study documents occupational exposure to waste anesthetic gases in PACU

Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Study: Genetics as well as environment in womb play important roles in development of baby

Researchers develop animal model of human hantavirus pulmonary syndrome

Scientists identify natural human antibodies against virus that causes MERS

Scientists extract infectious sample of MERS coronavirus from two camels in Saudi Arabia

Positive results from pivotal clinical trial of Trophos’ olesoxime in SMA patients to be presented at AAN 2014

Immunoregulatory genes modulate otitis media risk

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

Forest Laboratories enters into definitive agreement to acquire Furiex

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Mauna Kea receives regulatory approval in Japan for Cellvizio flagship product

Study: Depression affects more than one out of three critical care survivors

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News